Amgen's Sjögren's drug cuts disease activity in trialAmgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.Nov 11, 2026·2 sourcesDrug developmentClinical trial endpointsPharmaceutical IndustryAutoimmune diseaseAutoimmune disease treatmentsRandomized controlled trialBiologic therapiesClinical trials00
